2025 second_quarter Filing

Income

$50K

Filed

July 22, 2025

Lobbying Activities

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2023. S. 1097 Interagency Patent Coordination Act. Medication Affordability and Patent Integrity Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act H.R. 3160 & S. 1533, the PREVAIL Act S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025 S.43 Skinny Labels, Big Savings Act S. 1954, the Biosimilar Red Tape Elimination Act S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act S.1040 Drug Competition Enhancement Act

Contacted:HOUSE OF REPRESENTATIVES, SENATE

PharmacyView all

Issues related to prescription drug pricing. Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. Ensuring Timely Access to Generics Act. S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act.

HOUSE OF REPRESENTATIVES, SENATE

Lobbyists (3)

MARTIN WHITMER

Deputy CoS-USDOT

THOMAS WORRALL

ERIK KOMENDANT

Legislative Correspondent, Rep. Zoe Lofgren (CA); Legislative Director, Rep. Jason Altmire (PA); Policy Director, Blue Dog Coalition